Literature DB >> 6524906

In vitro antimicrobial susceptibility of a Mycobacterium sp. isolated from patients with Crohn's disease.

R J Chiodini, H J Van Kruiningen, W R Thayer, J A Coutu, R S Merkal.   

Abstract

The in vitro susceptibility of three strains of an unclassified Mycobacterium sp., isolated from three patients with Crohn's disease, to 23 antimicrobial agents was determined by a modified broth dilution method with 7H9 broth containing oleic acid-albumin-dextrose-catalase, Tween 80, and mycobactin J. All three strains were susceptible to streptomycin, viomycin, rifampin, clofazimine, cefazolin, amikacin, and kanamycin and resistant to p-aminosalicylic acid, cycloserine, 2-thiophenecarboxylic acid hydrazide, trimethoprim, diaminodiphenylsulfone, sulfamethoxazole, sulfadimethoxine, polymyxin B, metronidazole, neomycin, and carbenicillin. Variable results between strains were encountered with ethambutol, ethionamide, capreomycin, amoxicillin, and cephalothin.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6524906      PMCID： PMC180053          DOI： 10.1128/AAC.26.6.930

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Clinical effect of metronidazole and sulfasalazine on Crohn's disease in relation to changes in the fecal flora.

Authors:  A Krook; G Järnerot; D Danielsson
Journal:  Scand J Gastroenterol       Date:  1981       Impact factor: 2.423

2.  Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study.

Authors:  P A Van Hees; H J Van Lier; P H Van Elteren; M Driessen; R A Van Hogezand; G P Ten Velde; J H Bakker; J H Van Tongeren
Journal:  Gut       Date:  1981-05       Impact factor: 23.059

3.  In vitro susceptibility of Mycobacterium fortuitum to cefoxitin.

Authors:  M H Cynamon; A Patapow
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

4.  The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.

Authors:  A K Azadkhan; S C Truelove; J K Aronson
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

5.  In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.

Authors:  M H Cynamon; G S Palmer
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

6.  Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?

Authors:  N Rastogi; C Frehel; A Ryter; H Ohayon; M Lesourd; H L David
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

7.  Mechanism of antibiotic resistance in Mycobacterium intracellulare.

Authors:  Y Mizuguchi; T Udou; T Yamada
Journal:  Microbiol Immunol       Date:  1983       Impact factor: 1.955

8.  Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease.

Authors:  R J Chiodini; H J Van Kruiningen; R S Merkal; W R Thayer; J A Coutu
Journal:  J Clin Microbiol       Date:  1984-11       Impact factor: 5.948

9.  Treatment of Crohn's disease with peroral 5-aminosalicylic acid.

Authors:  S N Rasmussen; V Binder; K Maier; S Bondesen; C Fischer; U Klotz; S H Hansen; E F Hvidberg
Journal:  Gastroenterology       Date:  1983-12       Impact factor: 22.682

10.  Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease.

Authors:  R J Chiodini; H J Van Kruiningen; W R Thayer; R S Merkal; J A Coutu
Journal:  Dig Dis Sci       Date:  1984-12       Impact factor: 3.199
View more
  12 in total

1.  In the search of a cause of Crohn's disease.

Authors:  Govind K Makharia; Urvashi B Singh
Journal:  Indian J Gastroenterol       Date:  2009 Sep-Oct

2.  Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of Mycobacterium avium subsp. paratuberculosis.

Authors:  S L Williams; N B Harris; R G Barletta
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

3.  Bactericidal activities of various antimicrobial agents against human and animal isolates of Mycobacterium paratuberculosis.

Authors:  R J Chiodini
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 4.  Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria.

Authors:  K Hultén; A Almashhrawi; F A El-Zaatari; D Y Graham
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

5.  Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo.

Authors:  N H Afdhal; A Long; J Lennon; J Crowe; D P O'Donoghue
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

6.  Spheroplastic phase of mycobacteria isolated from patients with Crohn's disease.

Authors:  R J Chiodini; H J Van Kruiningen; W R Thayer; J A Coutu
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

7.  Use of restriction fragment length polymorphisms resolved by pulsed-field gel electrophoresis for subspecies identification of mycobacteria in the Mycobacterium avium complex and for isolation of DNA probes.

Authors:  J W Coffin; C Condon; C A Compston; K N Potter; L R Lamontagne; J Shafiq; D Y Kunimoto
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

8.  Preliminary report on isolation of mycobacteria from patients with Crohn's disease.

Authors:  G Gitnick; J Collins; B Beaman; D Brooks; M Arthur; T Imaeda; M Palieschesky
Journal:  Dig Dis Sci       Date:  1989-06       Impact factor: 3.199

9.  Use of rifabutin in treatment of systemic Mycobacterium paratuberculosis infection in mice.

Authors:  R J Chiodini; J M Kreeger; W R Thayer
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

10.  Experimental disease in infant goats induced by a Mycobacterium isolated from a patient with Crohn's disease. A preliminary report.

Authors:  H J Van Kruiningen; R J Chiodini; W R Thayer; J A Coutu; R S Merkal; P L Runnels
Journal:  Dig Dis Sci       Date:  1986-12       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.